Charles River Laboratories (NYSE:CRL) exceeds Q3 2026 expectations

What happened

Charles River Laboratories reported Q3 2026 revenue of $982.7 million, down 2.2% from a year earlier but 2.3% above analysts’ estimates. Adjusted earnings per share, or profit allocated to each share after specified adjustments, were $3.09, 4% above estimates. Management raised the midpoint of full-year adjusted earnings guidance to $11.45.

Confirmed

Global impact / market context

The revenue decline shows reported sales were weaker year over year despite beating forecasts. Higher operating and free cash flow margins, which indicate the share of revenue left after costs and cash generated, may help protect earnings and fund operations; raised guidance signals management expects adjusted earnings to improve.

Analyst inference

The quarter presents mixed signals: reported revenue fell, while organic revenue, which excludes certain effects such as acquisitions and currency changes, rose 4.7%. The five-year revenue growth rate was 3% annually, below the healthcare sector benchmark, suggesting growth remains a longer-term concern.

Confirmed

What to watch

1. Check whether reported revenue returns to year-over-year growth in later quarters, since continued declines could weaken the sales base even if adjusted earnings remain above forecasts. Analyst inference
2. Compare future organic revenue with reported revenue to see whether underlying demand can offset the decline; the article reports organic growth of 4.7% this quarter. Analyst inference
3. Track results against the raised full-year adjusted earnings guidance midpoint of $11.45, and watch whether operating and free cash flow margins remain above prior-year levels. Analyst inference

Evidence

• stockstory.org